Immunotherapy of urologic tumors: Principles and progress

Urologic Oncology

Volumn 7, Issue 2, 2002, Pages 45-56

  Broghammer, Elizabeth L ^a   Ratliff, Timothy L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Immune modulation; Immunotherapeutic approaches; Prostate adenocarcinoma; Renal cell carcinoma; Transitional cell carcinoma

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C595; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY J415; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN P21; PROTEIN P53; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; BLADDER CARCINOMA; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL TRANSFER; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXICITY; DRUG MECHANISM; GENE THERAPY; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOMODULATION; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR SUPPRESSOR GENE; URINARY TRACT CANCER; VACCINATION; ADOPTIVE TRANSFER; CANCER RESEARCH; DRUG EFFECT; DRUG TOLERABILITY; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; MACROPHAGE; TH1 CELL; TH2 CELL; TUMOR GROWTH; TUMOR IMMUNOLOGY;

ANTIBODY FORMATION; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; TH1 CELLS; TH2 CELLS; UROLOGIC NEOPLASMS;

EID: 0036118445     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(01)00151-X     Document Type: Review

References (86)

1. Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes
2. Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: Role of proteases
3. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma
4. Prostate cancer vaccines: Current status
5. MHC expression and immune mechanisms in prostate cancer
6. Wood differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection
7. Tumor immunology
8. Distinct role of antigen-specific T helper type Th1 and Th2 cells in tumor eradication in vivo
9. Immune selection in neoplasia: Towards a microevolutionary model of cancer development
10. The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors: Lessons from normal and immunodeficient mice
11. Cancer statistics, 2000
12. Spontaneous regression of metastatic renal cancer: Case report and literature review
13. Immunotherapy of bladder cancer
14. Human anti-mouse antibodies
15. Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibody
16. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6
17. Mucin expression by transitional cell carcinomas of the bladder
18. Targeting of bladder cancer with monoclonal antibody NCRC48: A possible approach for intravesical therapy
19. Preclinical evaluation of copper-67 labeled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer
20. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595
21. Prostatic epidermal growth factor receptors and their regulation by androgens
22. Epidermal-growth factor receptors in human bladder cancer: Comparison of invasive and superficial tumours
23. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
24. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49
25. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man
26. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues
27. 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients
28. Radioimmunoscintigraphy with in-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy
29. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
30. MN/CA/G250 as a potential target for immunotherapy of renal cell carcinomas
31. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: Implications for fractionated dose radioimmunotherapy
32. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes
33. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma
34. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
35. A novel population of expanded human CD3+ CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency
36. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity
37. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes
38. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2
39. Interferon-α primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-α as therapy for metastatic renal cell carcinoma
40. Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma
41. T-cell adoptive immunotherapy of metastatic renal cell carcinoma
42. Cancer. p53, guardian of the genome
43. Two distinct mechanisms regulate the levels of a cellular tumor antigen
44. Accumulation of nuclear p53 and tumor progression in bladder cancer
45. Immunotherapy of bladder cancer targeting p53
46. Adoptive immunotherapy prevents prostate cancer in transgenic animal model
47. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy
48. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical Bacillus Calmette-Guerin immunotherapy
49. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG
50. BCG treatment and the importance of an inflammatory response
51. IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis Bacillus Calmette-Guerin immunotherapy
52. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
53. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
54. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
55. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
56. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer
57. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma
58. Continuous intra-arterial administration of recombinant interleukin-2 in low stage bladder cancer
59. Local continuous high dose interleukin 2: A new therapeutic model for the treatment of advanced bladder carcinoma
60. A phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with superficial bladder cancer
61. Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: A follow-up study
62. Tumour regression after intralesional injection of interleukin-2 (IL-2) in bladder cancer. Preliminary report
63. Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder
64. Superficial bladder cancer: The role of interferon-α
65. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): Multicenter trial comparing Bacille Calmette-Guerin and interferon-alpha
66. BCG vs BCG plus recombinant α-interferon 2b in superficial tumors of the bladder
67. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes
68. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calemtte-Guerin immunotherapy
69. Intratumoral depot interleukin-2 therapy inhibits tumor growth in Dunning adenocarcinoma of the prostate implanted subcutaneously in rats
70. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo
71. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth
72. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
73. Recombinant vaccinia-PSA (Prostvac) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
74. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
75. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide
76. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
77. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
78. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
79. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines
80. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation
81. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
82. Dendritic cell based immunotherapy of prostate cancer
83. Follow-up evaluation of a phase II prostate cancer vaccine trial
84. IL-12 and mutant p53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer
85. Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma